nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—Folic Acid Metabolism Inhibitors—Methotrexate—testicular cancer	0.327	1	CiPCiCtD
Pemetrexed—Methotrexate—testicular cancer	0.212	1	CrCtD
Pemetrexed—lung cancer—testicular cancer	0.173	1	CtDrD
Pemetrexed—ATIC—Methotrexate—testicular cancer	0.041	0.377	CbGbCtD
Pemetrexed—SLC46A1—Methotrexate—testicular cancer	0.0326	0.299	CbGbCtD
Pemetrexed—Tetrahydrofolic acid—Methotrexate—testicular cancer	0.028	0.2	CrCrCtD
Pemetrexed—Leucovorin—Methotrexate—testicular cancer	0.028	0.2	CrCrCtD
Pemetrexed—Folic Acid—Methotrexate—testicular cancer	0.028	0.2	CrCrCtD
Pemetrexed—Pralatrexate—Methotrexate—testicular cancer	0.028	0.2	CrCrCtD
Pemetrexed—Raltitrexed—Methotrexate—testicular cancer	0.028	0.2	CrCrCtD
Pemetrexed—DHFR—Methotrexate—testicular cancer	0.0208	0.191	CbGbCtD
Pemetrexed—TYMS—Methotrexate—testicular cancer	0.0145	0.133	CbGbCtD
Pemetrexed—GART—seminal vesicle—testicular cancer	0.000899	0.0769	CbGeAlD
Pemetrexed—SLC46A1—seminal vesicle—testicular cancer	0.00073	0.0624	CbGeAlD
Pemetrexed—ATIC—embryo—testicular cancer	0.00065	0.0556	CbGeAlD
Pemetrexed—GART—gonad—testicular cancer	0.00065	0.0555	CbGeAlD
Pemetrexed—GART—female gonad—testicular cancer	0.000528	0.0451	CbGeAlD
Pemetrexed—GART—testis—testicular cancer	0.000468	0.04	CbGeAlD
Pemetrexed—ATIC—gonad—testicular cancer	0.000441	0.0377	CbGeAlD
Pemetrexed—DHFR—embryo—testicular cancer	0.000436	0.0373	CbGeAlD
Pemetrexed—SLC46A1—female gonad—testicular cancer	0.000429	0.0366	CbGeAlD
Pemetrexed—DHFR—seminal vesicle—testicular cancer	0.00041	0.035	CbGeAlD
Pemetrexed—SLC46A1—testis—testicular cancer	0.00038	0.0325	CbGeAlD
Pemetrexed—DCK—embryo—testicular cancer	0.000378	0.0323	CbGeAlD
Pemetrexed—ATIC—female gonad—testicular cancer	0.000358	0.0306	CbGeAlD
Pemetrexed—DCK—seminal vesicle—testicular cancer	0.000355	0.0303	CbGeAlD
Pemetrexed—GART—lymph node—testicular cancer	0.000339	0.029	CbGeAlD
Pemetrexed—ATIC—testis—testicular cancer	0.000318	0.0272	CbGeAlD
Pemetrexed—TYMS—gonad—testicular cancer	0.000299	0.0256	CbGeAlD
Pemetrexed—DHFR—gonad—testicular cancer	0.000296	0.0253	CbGeAlD
Pemetrexed—SLC46A1—lymph node—testicular cancer	0.000276	0.0236	CbGeAlD
Pemetrexed—SLC29A1—gonad—testicular cancer	0.000268	0.0229	CbGeAlD
Pemetrexed—DCK—gonad—testicular cancer	0.000256	0.0219	CbGeAlD
Pemetrexed—TYMS—female gonad—testicular cancer	0.000243	0.0208	CbGeAlD
Pemetrexed—DHFR—female gonad—testicular cancer	0.000241	0.0206	CbGeAlD
Pemetrexed—ATIC—lymph node—testicular cancer	0.00023	0.0197	CbGeAlD
Pemetrexed—SLC29A1—female gonad—testicular cancer	0.000218	0.0186	CbGeAlD
Pemetrexed—TYMS—testis—testicular cancer	0.000216	0.0184	CbGeAlD
Pemetrexed—DHFR—testis—testicular cancer	0.000213	0.0183	CbGeAlD
Pemetrexed—DCK—female gonad—testicular cancer	0.000208	0.0178	CbGeAlD
Pemetrexed—SLC29A1—testis—testicular cancer	0.000193	0.0165	CbGeAlD
Pemetrexed—DCK—testis—testicular cancer	0.000185	0.0158	CbGeAlD
Pemetrexed—TYMS—lymph node—testicular cancer	0.000156	0.0134	CbGeAlD
Pemetrexed—DHFR—lymph node—testicular cancer	0.000155	0.0132	CbGeAlD
Pemetrexed—SLC29A1—lymph node—testicular cancer	0.00014	0.012	CbGeAlD
Pemetrexed—TYMS—Vinorelbine—Vinblastine—testicular cancer	0.000139	0.239	CbGdCrCtD
Pemetrexed—TYMS—Podofilox—Etoposide—testicular cancer	0.000139	0.239	CbGdCrCtD
Pemetrexed—DCK—lymph node—testicular cancer	0.000134	0.0114	CbGeAlD
Pemetrexed—TYMS—Vincristine—Vinblastine—testicular cancer	0.000119	0.204	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—testicular cancer	9.6e-05	0.165	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—testicular cancer	8.88e-05	0.153	CbGdCrCtD
Pemetrexed—Anorexia—Cisplatin—testicular cancer	2.76e-05	0.00101	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Etoposide—testicular cancer	2.75e-05	0.001	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Ifosfamide—testicular cancer	2.75e-05	0.001	CcSEcCtD
Pemetrexed—Pancreatitis—Methotrexate—testicular cancer	2.74e-05	0.001	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—testicular cancer	2.73e-05	0.000994	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—testicular cancer	2.73e-05	0.000994	CcSEcCtD
Pemetrexed—Hypersensitivity—Dactinomycin—testicular cancer	2.7e-05	0.000986	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—testicular cancer	2.67e-05	0.000974	CcSEcCtD
Pemetrexed—Urticaria—Ifosfamide—testicular cancer	2.67e-05	0.000974	CcSEcCtD
Pemetrexed—Abdominal pain—Ifosfamide—testicular cancer	2.66e-05	0.000969	CcSEcCtD
Pemetrexed—Body temperature increased—Ifosfamide—testicular cancer	2.66e-05	0.000969	CcSEcCtD
Pemetrexed—Pancytopenia—Methotrexate—testicular cancer	2.66e-05	0.000969	CcSEcCtD
Pemetrexed—Anaphylactic shock—Etoposide—testicular cancer	2.66e-05	0.000968	CcSEcCtD
Pemetrexed—Mood swings—Doxorubicin—testicular cancer	2.65e-05	0.000968	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Cisplatin—testicular cancer	2.64e-05	0.000963	CcSEcCtD
Pemetrexed—Infection—Etoposide—testicular cancer	2.64e-05	0.000962	CcSEcCtD
Pemetrexed—Asthenia—Dactinomycin—testicular cancer	2.63e-05	0.00096	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—testicular cancer	2.63e-05	0.000957	CcSEcCtD
Pemetrexed—Dysphagia—Epirubicin—testicular cancer	2.62e-05	0.000954	CcSEcCtD
Pemetrexed—Neutropenia—Methotrexate—testicular cancer	2.62e-05	0.000954	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—testicular cancer	2.61e-05	0.00095	CcSEcCtD
Pemetrexed—Thrombocytopenia—Etoposide—testicular cancer	2.6e-05	0.000948	CcSEcCtD
Pemetrexed—Dyspnoea—Cisplatin—testicular cancer	2.58e-05	0.000942	CcSEcCtD
Pemetrexed—Skin disorder—Etoposide—testicular cancer	2.58e-05	0.00094	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—testicular cancer	2.57e-05	0.000936	CcSEcCtD
Pemetrexed—Angina pectoris—Epirubicin—testicular cancer	2.55e-05	0.00093	CcSEcCtD
Pemetrexed—Anorexia—Etoposide—testicular cancer	2.53e-05	0.000923	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	2.52e-05	0.00092	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—testicular cancer	2.52e-05	0.00092	CcSEcCtD
Pemetrexed—Decreased appetite—Cisplatin—testicular cancer	2.52e-05	0.000919	CcSEcCtD
Pemetrexed—Diarrhoea—Dactinomycin—testicular cancer	2.51e-05	0.000915	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Cisplatin—testicular cancer	2.5e-05	0.000912	CcSEcCtD
Pemetrexed—Vomiting—Bleomycin—testicular cancer	2.5e-05	0.000912	CcSEcCtD
Pemetrexed—Infestation NOS—Methotrexate—testicular cancer	2.49e-05	0.000909	CcSEcCtD
Pemetrexed—Infestation—Methotrexate—testicular cancer	2.49e-05	0.000909	CcSEcCtD
Pemetrexed—Pancytopenia—Epirubicin—testicular cancer	2.49e-05	0.000906	CcSEcCtD
Pemetrexed—Rash—Bleomycin—testicular cancer	2.48e-05	0.000904	CcSEcCtD
Pemetrexed—Pain—Cisplatin—testicular cancer	2.48e-05	0.000904	CcSEcCtD
Pemetrexed—Dermatitis—Bleomycin—testicular cancer	2.48e-05	0.000904	CcSEcCtD
Pemetrexed—Hypersensitivity—Ifosfamide—testicular cancer	2.48e-05	0.000903	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Methotrexate—testicular cancer	2.47e-05	0.000902	CcSEcCtD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—testicular cancer	2.47e-05	0.000901	CcSEcCtD
Pemetrexed—Renal failure—Methotrexate—testicular cancer	2.45e-05	0.000894	CcSEcCtD
Pemetrexed—Neutropenia—Epirubicin—testicular cancer	2.45e-05	0.000892	CcSEcCtD
Pemetrexed—Stomatitis—Methotrexate—testicular cancer	2.43e-05	0.000886	CcSEcCtD
Pemetrexed—Conjunctivitis—Methotrexate—testicular cancer	2.42e-05	0.000884	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—testicular cancer	2.42e-05	0.000883	CcSEcCtD
Pemetrexed—Asthenia—Ifosfamide—testicular cancer	2.41e-05	0.00088	CcSEcCtD
Pemetrexed—Pruritus—Ifosfamide—testicular cancer	2.38e-05	0.000867	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—testicular cancer	2.37e-05	0.000866	CcSEcCtD
Pemetrexed—Dyspnoea—Etoposide—testicular cancer	2.37e-05	0.000863	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—testicular cancer	2.36e-05	0.00086	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Methotrexate—testicular cancer	2.36e-05	0.00086	CcSEcCtD
Pemetrexed—Nausea—Bleomycin—testicular cancer	2.34e-05	0.000852	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—testicular cancer	2.33e-05	0.000851	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—testicular cancer	2.33e-05	0.000851	CcSEcCtD
Pemetrexed—Vomiting—Dactinomycin—testicular cancer	2.33e-05	0.000851	CcSEcCtD
Pemetrexed—Agranulocytosis—Methotrexate—testicular cancer	2.33e-05	0.000849	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—testicular cancer	2.31e-05	0.000844	CcSEcCtD
Pemetrexed—Rash—Dactinomycin—testicular cancer	2.31e-05	0.000843	CcSEcCtD
Pemetrexed—Decreased appetite—Etoposide—testicular cancer	2.31e-05	0.000842	CcSEcCtD
Pemetrexed—Diarrhoea—Ifosfamide—testicular cancer	2.3e-05	0.000839	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—testicular cancer	2.3e-05	0.000839	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—testicular cancer	2.29e-05	0.000837	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Etoposide—testicular cancer	2.29e-05	0.000836	CcSEcCtD
Pemetrexed—Body temperature increased—Cisplatin—testicular cancer	2.29e-05	0.000835	CcSEcCtD
Pemetrexed—Fatigue—Etoposide—testicular cancer	2.29e-05	0.000835	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—testicular cancer	2.29e-05	0.000834	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—testicular cancer	2.28e-05	0.000829	CcSEcCtD
Pemetrexed—Pain—Etoposide—testicular cancer	2.27e-05	0.000828	CcSEcCtD
Pemetrexed—Constipation—Etoposide—testicular cancer	2.27e-05	0.000828	CcSEcCtD
Pemetrexed—Conjunctivitis—Epirubicin—testicular cancer	2.27e-05	0.000827	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—testicular cancer	2.26e-05	0.000826	CcSEcCtD
Pemetrexed—Hepatitis—Methotrexate—testicular cancer	2.24e-05	0.000816	CcSEcCtD
Pemetrexed—Dizziness—Ifosfamide—testicular cancer	2.22e-05	0.000811	CcSEcCtD
Pemetrexed—Pharyngitis—Methotrexate—testicular cancer	2.22e-05	0.00081	CcSEcCtD
Pemetrexed—Urinary tract disorder—Methotrexate—testicular cancer	2.21e-05	0.000806	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Epirubicin—testicular cancer	2.21e-05	0.000805	CcSEcCtD
Pemetrexed—Urethral disorder—Methotrexate—testicular cancer	2.19e-05	0.0008	CcSEcCtD
Pemetrexed—Nausea—Dactinomycin—testicular cancer	2.18e-05	0.000795	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—testicular cancer	2.18e-05	0.000794	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Etoposide—testicular cancer	2.17e-05	0.000792	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—testicular cancer	2.16e-05	0.000787	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—testicular cancer	2.16e-05	0.000787	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	2.14e-05	0.000781	CcSEcCtD
Pemetrexed—Vomiting—Ifosfamide—testicular cancer	2.14e-05	0.000779	CcSEcCtD
Pemetrexed—Hypersensitivity—Cisplatin—testicular cancer	2.14e-05	0.000779	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—testicular cancer	2.12e-05	0.000774	CcSEcCtD
Pemetrexed—Rash—Ifosfamide—testicular cancer	2.12e-05	0.000773	CcSEcCtD
Pemetrexed—Dermatitis—Ifosfamide—testicular cancer	2.12e-05	0.000772	CcSEcCtD
Pemetrexed—Erythema multiforme—Methotrexate—testicular cancer	2.12e-05	0.000772	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—testicular cancer	2.12e-05	0.000772	CcSEcCtD
Pemetrexed—Urticaria—Etoposide—testicular cancer	2.11e-05	0.000769	CcSEcCtD
Pemetrexed—Stomatitis—Doxorubicin—testicular cancer	2.11e-05	0.000768	CcSEcCtD
Pemetrexed—Body temperature increased—Etoposide—testicular cancer	2.1e-05	0.000765	CcSEcCtD
Pemetrexed—Abdominal pain—Etoposide—testicular cancer	2.1e-05	0.000765	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—testicular cancer	2.1e-05	0.000765	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—testicular cancer	2.1e-05	0.000764	CcSEcCtD
Pemetrexed—Eye disorder—Methotrexate—testicular cancer	2.09e-05	0.000763	CcSEcCtD
Pemetrexed—Asthenia—Cisplatin—testicular cancer	2.08e-05	0.000758	CcSEcCtD
Pemetrexed—Pharyngitis—Epirubicin—testicular cancer	2.08e-05	0.000758	CcSEcCtD
Pemetrexed—Urinary tract disorder—Epirubicin—testicular cancer	2.07e-05	0.000754	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—testicular cancer	2.05e-05	0.000749	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—testicular cancer	2.04e-05	0.000745	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—testicular cancer	2.02e-05	0.000735	CcSEcCtD
Pemetrexed—Nausea—Ifosfamide—testicular cancer	2e-05	0.000728	CcSEcCtD
Pemetrexed—Diarrhoea—Cisplatin—testicular cancer	1.98e-05	0.000723	CcSEcCtD
Pemetrexed—Erythema multiforme—Epirubicin—testicular cancer	1.98e-05	0.000722	CcSEcCtD
Pemetrexed—Alopecia—Methotrexate—testicular cancer	1.98e-05	0.000721	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—testicular cancer	1.96e-05	0.000714	CcSEcCtD
Pemetrexed—Hypersensitivity—Etoposide—testicular cancer	1.96e-05	0.000713	CcSEcCtD
Pemetrexed—Erythema—Methotrexate—testicular cancer	1.95e-05	0.000711	CcSEcCtD
Pemetrexed—Malnutrition—Methotrexate—testicular cancer	1.95e-05	0.000711	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—testicular cancer	1.94e-05	0.000707	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—testicular cancer	1.92e-05	0.000702	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—testicular cancer	1.91e-05	0.000698	CcSEcCtD
Pemetrexed—Dysgeusia—Methotrexate—testicular cancer	1.91e-05	0.000696	CcSEcCtD
Pemetrexed—Asthenia—Etoposide—testicular cancer	1.91e-05	0.000695	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—testicular cancer	1.9e-05	0.000693	CcSEcCtD
Pemetrexed—Pruritus—Etoposide—testicular cancer	1.88e-05	0.000685	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—testicular cancer	1.87e-05	0.000682	CcSEcCtD
Pemetrexed—Alopecia—Epirubicin—testicular cancer	1.85e-05	0.000675	CcSEcCtD
Pemetrexed—Vomiting—Cisplatin—testicular cancer	1.84e-05	0.000672	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—testicular cancer	1.83e-05	0.000668	CcSEcCtD
Pemetrexed—Rash—Cisplatin—testicular cancer	1.83e-05	0.000666	CcSEcCtD
Pemetrexed—Dermatitis—Cisplatin—testicular cancer	1.83e-05	0.000666	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—testicular cancer	1.82e-05	0.000665	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—testicular cancer	1.82e-05	0.000665	CcSEcCtD
Pemetrexed—Diarrhoea—Etoposide—testicular cancer	1.82e-05	0.000662	CcSEcCtD
Pemetrexed—Eye disorder—Doxorubicin—testicular cancer	1.81e-05	0.000661	CcSEcCtD
Pemetrexed—Anaemia—Methotrexate—testicular cancer	1.8e-05	0.000657	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—testicular cancer	1.79e-05	0.000651	CcSEcCtD
Pemetrexed—Dizziness—Etoposide—testicular cancer	1.76e-05	0.00064	CcSEcCtD
Pemetrexed—Leukopenia—Methotrexate—testicular cancer	1.74e-05	0.000636	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—testicular cancer	1.73e-05	0.000631	CcSEcCtD
Pemetrexed—Nausea—Cisplatin—testicular cancer	1.72e-05	0.000628	CcSEcCtD
Pemetrexed—Alopecia—Doxorubicin—testicular cancer	1.71e-05	0.000625	CcSEcCtD
Pemetrexed—Vomiting—Etoposide—testicular cancer	1.69e-05	0.000616	CcSEcCtD
Pemetrexed—Malnutrition—Doxorubicin—testicular cancer	1.69e-05	0.000615	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—testicular cancer	1.69e-05	0.000615	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—testicular cancer	1.69e-05	0.000615	CcSEcCtD
Pemetrexed—Rash—Etoposide—testicular cancer	1.67e-05	0.00061	CcSEcCtD
Pemetrexed—Dermatitis—Etoposide—testicular cancer	1.67e-05	0.00061	CcSEcCtD
Pemetrexed—Chest pain—Methotrexate—testicular cancer	1.66e-05	0.000605	CcSEcCtD
Pemetrexed—Myalgia—Methotrexate—testicular cancer	1.66e-05	0.000605	CcSEcCtD
Pemetrexed—Arthralgia—Methotrexate—testicular cancer	1.66e-05	0.000605	CcSEcCtD
Pemetrexed—Dysgeusia—Doxorubicin—testicular cancer	1.65e-05	0.000603	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	1.65e-05	0.000601	CcSEcCtD
Pemetrexed—Syncope—Epirubicin—testicular cancer	1.64e-05	0.000596	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—testicular cancer	1.63e-05	0.000595	CcSEcCtD
Pemetrexed—Loss of consciousness—Epirubicin—testicular cancer	1.6e-05	0.000584	CcSEcCtD
Pemetrexed—Anaphylactic shock—Methotrexate—testicular cancer	1.59e-05	0.00058	CcSEcCtD
Pemetrexed—Infection—Methotrexate—testicular cancer	1.58e-05	0.000576	CcSEcCtD
Pemetrexed—Nausea—Etoposide—testicular cancer	1.58e-05	0.000575	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—testicular cancer	1.57e-05	0.000574	CcSEcCtD
Pemetrexed—Nervous system disorder—Methotrexate—testicular cancer	1.56e-05	0.000569	CcSEcCtD
Pemetrexed—Anaemia—Doxorubicin—testicular cancer	1.56e-05	0.000569	CcSEcCtD
Pemetrexed—Thrombocytopenia—Methotrexate—testicular cancer	1.56e-05	0.000568	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—testicular cancer	1.55e-05	0.000566	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—testicular cancer	1.55e-05	0.000566	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—testicular cancer	1.55e-05	0.000566	CcSEcCtD
Pemetrexed—Skin disorder—Methotrexate—testicular cancer	1.55e-05	0.000563	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	1.54e-05	0.000562	CcSEcCtD
Pemetrexed—Anorexia—Methotrexate—testicular cancer	1.52e-05	0.000553	CcSEcCtD
Pemetrexed—Syncope—Doxorubicin—testicular cancer	1.51e-05	0.000552	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—testicular cancer	1.51e-05	0.000551	CcSEcCtD
Pemetrexed—Oedema—Epirubicin—testicular cancer	1.49e-05	0.000543	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—testicular cancer	1.49e-05	0.000543	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—testicular cancer	1.48e-05	0.000541	CcSEcCtD
Pemetrexed—Infection—Epirubicin—testicular cancer	1.48e-05	0.000539	CcSEcCtD
Pemetrexed—Shock—Epirubicin—testicular cancer	1.46e-05	0.000534	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—testicular cancer	1.46e-05	0.000532	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—testicular cancer	1.46e-05	0.000531	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—testicular cancer	1.46e-05	0.000531	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Methotrexate—testicular cancer	1.45e-05	0.000528	CcSEcCtD
Pemetrexed—Skin disorder—Epirubicin—testicular cancer	1.45e-05	0.000527	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—testicular cancer	1.44e-05	0.000524	CcSEcCtD
Pemetrexed—Chest pain—Doxorubicin—testicular cancer	1.44e-05	0.000524	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—testicular cancer	1.44e-05	0.000524	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	1.43e-05	0.00052	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—testicular cancer	1.42e-05	0.000517	CcSEcCtD
Pemetrexed—Dyspnoea—Methotrexate—testicular cancer	1.42e-05	0.000517	CcSEcCtD
Pemetrexed—Dyspepsia—Methotrexate—testicular cancer	1.4e-05	0.000511	CcSEcCtD
Pemetrexed—Decreased appetite—Methotrexate—testicular cancer	1.38e-05	0.000504	CcSEcCtD
Pemetrexed—Oedema—Doxorubicin—testicular cancer	1.38e-05	0.000502	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—testicular cancer	1.38e-05	0.000502	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Methotrexate—testicular cancer	1.37e-05	0.000501	CcSEcCtD
Pemetrexed—Fatigue—Methotrexate—testicular cancer	1.37e-05	0.0005	CcSEcCtD
Pemetrexed—Infection—Doxorubicin—testicular cancer	1.37e-05	0.000499	CcSEcCtD
Pemetrexed—Pain—Methotrexate—testicular cancer	1.36e-05	0.000496	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—testicular cancer	1.36e-05	0.000494	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—testicular cancer	1.36e-05	0.000494	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—testicular cancer	1.35e-05	0.000492	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—testicular cancer	1.35e-05	0.000492	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—testicular cancer	1.34e-05	0.000488	CcSEcCtD
Pemetrexed—Dyspnoea—Epirubicin—testicular cancer	1.33e-05	0.000484	CcSEcCtD
Pemetrexed—Anorexia—Doxorubicin—testicular cancer	1.31e-05	0.000479	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—testicular cancer	1.31e-05	0.000478	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Methotrexate—testicular cancer	1.3e-05	0.000474	CcSEcCtD
Pemetrexed—Decreased appetite—Epirubicin—testicular cancer	1.29e-05	0.000472	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—testicular cancer	1.29e-05	0.000469	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—testicular cancer	1.28e-05	0.000468	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—testicular cancer	1.27e-05	0.000464	CcSEcCtD
Pemetrexed—Pain—Epirubicin—testicular cancer	1.27e-05	0.000464	CcSEcCtD
Pemetrexed—Urticaria—Methotrexate—testicular cancer	1.26e-05	0.000461	CcSEcCtD
Pemetrexed—Abdominal pain—Methotrexate—testicular cancer	1.26e-05	0.000458	CcSEcCtD
Pemetrexed—Body temperature increased—Methotrexate—testicular cancer	1.26e-05	0.000458	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—testicular cancer	1.25e-05	0.000458	CcSEcCtD
Pemetrexed—Dyspnoea—Doxorubicin—testicular cancer	1.23e-05	0.000448	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Epirubicin—testicular cancer	1.22e-05	0.000444	CcSEcCtD
Pemetrexed—Dyspepsia—Doxorubicin—testicular cancer	1.21e-05	0.000442	CcSEcCtD
Pemetrexed—Decreased appetite—Doxorubicin—testicular cancer	1.2e-05	0.000437	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—testicular cancer	1.19e-05	0.000434	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—testicular cancer	1.19e-05	0.000433	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—testicular cancer	1.18e-05	0.000431	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—testicular cancer	1.18e-05	0.000429	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—testicular cancer	1.18e-05	0.000429	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—testicular cancer	1.18e-05	0.000429	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—testicular cancer	1.18e-05	0.000429	CcSEcCtD
Pemetrexed—Hypersensitivity—Methotrexate—testicular cancer	1.17e-05	0.000427	CcSEcCtD
Pemetrexed—Asthenia—Methotrexate—testicular cancer	1.14e-05	0.000416	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Doxorubicin—testicular cancer	1.13e-05	0.000411	CcSEcCtD
Pemetrexed—Pruritus—Methotrexate—testicular cancer	1.13e-05	0.00041	CcSEcCtD
Pemetrexed—Hypersensitivity—Epirubicin—testicular cancer	1.1e-05	0.0004	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—testicular cancer	1.09e-05	0.000399	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—testicular cancer	1.09e-05	0.000397	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—testicular cancer	1.09e-05	0.000397	CcSEcCtD
Pemetrexed—Diarrhoea—Methotrexate—testicular cancer	1.09e-05	0.000397	CcSEcCtD
Pemetrexed—Asthenia—Epirubicin—testicular cancer	1.07e-05	0.000389	CcSEcCtD
Pemetrexed—Pruritus—Epirubicin—testicular cancer	1.05e-05	0.000384	CcSEcCtD
Pemetrexed—Dizziness—Methotrexate—testicular cancer	1.05e-05	0.000384	CcSEcCtD
Pemetrexed—Diarrhoea—Epirubicin—testicular cancer	1.02e-05	0.000371	CcSEcCtD
Pemetrexed—Hypersensitivity—Doxorubicin—testicular cancer	1.01e-05	0.00037	CcSEcCtD
Pemetrexed—Vomiting—Methotrexate—testicular cancer	1.01e-05	0.000369	CcSEcCtD
Pemetrexed—Rash—Methotrexate—testicular cancer	1e-05	0.000366	CcSEcCtD
Pemetrexed—Dermatitis—Methotrexate—testicular cancer	1e-05	0.000365	CcSEcCtD
Pemetrexed—Asthenia—Doxorubicin—testicular cancer	9.88e-06	0.00036	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—testicular cancer	9.84e-06	0.000359	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—testicular cancer	9.74e-06	0.000355	CcSEcCtD
Pemetrexed—Vomiting—Epirubicin—testicular cancer	9.46e-06	0.000345	CcSEcCtD
Pemetrexed—Nausea—Methotrexate—testicular cancer	9.45e-06	0.000344	CcSEcCtD
Pemetrexed—Diarrhoea—Doxorubicin—testicular cancer	9.42e-06	0.000344	CcSEcCtD
Pemetrexed—Rash—Epirubicin—testicular cancer	9.39e-06	0.000342	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—testicular cancer	9.38e-06	0.000342	CcSEcCtD
Pemetrexed—Dizziness—Doxorubicin—testicular cancer	9.11e-06	0.000332	CcSEcCtD
Pemetrexed—Nausea—Epirubicin—testicular cancer	8.84e-06	0.000322	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—testicular cancer	8.76e-06	0.000319	CcSEcCtD
Pemetrexed—Rash—Doxorubicin—testicular cancer	8.68e-06	0.000317	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—testicular cancer	8.68e-06	0.000316	CcSEcCtD
Pemetrexed—Nausea—Doxorubicin—testicular cancer	8.18e-06	0.000298	CcSEcCtD
